The newest gonadotropin-releasing hormone (GnRH) antagonist therapy drug, degarelix (aka Firmagon) has become more commonly used in everyday clinical practice as an alternative hormone therapy treatment drug (ADT). Given that its use has become common it is important to understand both its safety and efficacy as compared to our older standard drugs. The best way [...]
It is a little out of the normal scope of this blog, but a recent prostate cancer study from Canada has received a lot of buzz and needs some commentary and analysis. The study concluded that for men who are diagnosed with local prostate cancer (still confined in the gland) live longer if they have [...]
NICE, which serves as a cost-effectiveness agency has said in a draft guidance that it supports the use of Xtandi (enzalutamide) in men whose prostate cancer has spread after the failure of first-line therapy (i.e. ADT), but for whom chemotherapy is not yet necessary. The agency found that Xtandi can delay the need for chemotherapy, [...]
As we reach this holiday season I want to remind you that Malecare has been working to help you and your family survive longer and have a better quality of life. We have helped you in ways that you are aware of; like through this blog and by the Malecare Advanced Prostate Cancer Online Support Group. [...]
We have some good news, the United States Congress has passed the Omnibus spending package. The package will fund the U.S. Government through fiscal 2016. We should take note that this bill includes a $2 billion increase for the National Institute of Health (NIH), a 5% increase for the National Cancer Institute (NCI) and the [...]